The Innovation Support Unit’s mission is to foster, boost and disseminate an innovative culture, providing a suitable framework in which to create multi-institutional and inter-disciplinary teams that can come together and collaborate in the joint design of technologies, and so enable them to find solutions to as yet unresolved clinical problems.
The Unit’s objective is to convert ideas into benefits for the patients and wealth for the country.
The Unit therefore applies the guidelines of Standard UNE 166002:2014 “R&D&I Management Systems” and, as endorsement of its consistency with the said standard, holds the Certificate for its System issued by AENOR.
Among the System documents is the R&D&i Policy, a declaration of intent regarding the future management and approach of this Biodonostia HRI strategic process and which, as a requirement of the Standard, must be made available to interested parties external to the Institute.
It acts as a bridge between the members of the first Health Research Institute in the Basque Country, in the exceptional setting of San Sebastián, which includes the Health R+D, Universities, Research Centres, Technology Centres and Companies.
The Innovation Support Unit, through its participation in the Medical Technology Innovation Network (ITEMAS), aims to boost translational research by generating innovation in the non-pharmacological sector of medical and health technologies and material, as regards equipment, devices, reagents, materials and ICT in healthcare. Nowadays the Biodonostia HRI takes part in the ITEMAS Management Board whose role is to support the network Coordinator on its key duties.
The Institute, through the Innovation Support Unit, has taken part in the Trans-border Network for Biomedical Research of the Pyrenees, REFBIO II, funded by POCTEFA (European Union Programme for Territorial Co-operation INTERREG V-A Spain-France-Andorra) aimed at promoting sustainable development of the border territory of the three countries.
Earlier, in REFBIO I, nine co-operative research projects were carried out with the participation of IIS Biodonostia.
Our activities are mainly aimed at ensuring that the R+D results from the public-private collaboration reach society as a whole:
- Offering support from the moment a clinical need is detected by a health worker.
- Carrying out a search and assessment of already existing technological solutions.
- Search for partners and advice on the preparation of R+D projects.
- Search for funding.
- Advice to researchers on intellectual property.
- Advice to researchers on exploitation of results agreements.
- Negotiating with third parties for intellectual property licences and exploitation of results in projects in which the Institute participates.
- Ferritin-Mediated siRNA Delivery and Gene Silencing in Human Tumor and Primary cells.
- Cancer risk in DM1 is sex-related and linked to miRNA-200/141 downregulation.
- Identification and Characterization of the Dermal Panniculus Carnosus Muscle Stem Cells.
- SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression.
- Conjugated Polymers As Molecular Gates for Light-Controlled Release of Gold Nanoparticles.
- Novel lncRNA T-UCR as a potential downstream driver of the Wnt/β-catenin pathway in hepatobiliary carcinogenesis (Epub ahead of print).
- Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
- Guide to Best Practices in Innovation Management.
- Guide to Implementation of the Innovation Management System according to standard UNE 166002:2014.
- Guide to Best Practices in Innovative Public Purchasing.
LIST OF PATENTS REQUESTED / OBTAINED
- Mutation detecting device.
- Procedures and compositions for diagnosing and treating adrenoleukodystrophy.
- New compounds for regulating intracellular calcium homeostasis.
- Biomarkers of colorrectal cancer.
- New dual therapeutic strategy for the treatment of polycystic hepatic diseases.
- Multiple sclerosis animal model app.
- Diagnostic and prognostic biomarkers of frailty.
- Device for the study of a person’s Functional Capacity.
- Cell Therapy in the Treatment of Urinary Incontinence and Muscular Dystrophies.
PRODUCTS ON THE MARKET
The Innovation Support Unit team is lead by Dr Julio Arrizabalaga, head of the Medical Technology Innovation Network Platform (ITEMAS) and made up of the following members:
- Ph.D. Arantza Abad Alba: Innovation Support Unit Administrator: responsible for administration at the Innovation Support Unit.
- Ph.D. Olatz Arrizabalaga Garde: R&D&i Management and Scientific Coordination.
- PhD. Amaia Del Villar Álvarez: Innovation Support Unit External Agents Coordination.
- Ph.D. Ander Izeta Permisán: Head Scientific Officer at the Innovation Support Unit: responsible for the scientific aspects of the projects carried out within the Innovation Support Unit.
- Ignacio Aguirrezabala Herreras: Innovation Support Unit Innovation Management Technician.
- Helga Anso Amenabar: Head of Technological Transfer at Innovation Support Unit: advice to researchers on the Subject of Intellectual Property and ollaboration and Exploitation Agreements.
- Marisabel Arzamendi Sesé: Project Unit Manager. R&D&i project administrative management. Competitive fund search.
- Julián de Frutos Soto: Evaluation-Quality Unit Manager. ISU (Innovation Support Unit) Advanced Technician for the R&D&I Management System certified by AENOR based on the UNE 166002 Standard. Labour Risk Prevention Technician (LRP).
- Amaia Rodríguez Fernández: Coordination of Health Care Activities.
Julián de Frutos Soto
Tfno.: + 34 943 006129